{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T19:35:23Z","timestamp":1773171323066,"version":"3.50.1"},"reference-count":0,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2020,9,15]]},"DOI":"10.1001\/jama.2020.16783","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T15:02:46Z","timestamp":1600182166000},"page":"1026","source":"Crossref","is-referenced-by-count":4,"title":["Oral Drug Approved for Spinal Muscular Atrophy"],"prefix":"10.1001","volume":"324","author":[{"given":"Mary Chris","family":"Jaklevic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2770606\/jama_jaklevic_2020_fd_200046_1600069988.26742.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T15:02:46Z","timestamp":1600182166000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2770606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":0,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,9,15]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.16783","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,15]]}}}